Evidence map›Paper›PMID 32423115›Full record

ArticleJournal of clinical medicine2020

The Use of Donor-Derived Cell-Free DNA for Assessment of Allograft Rejection and Injury Status.

Charat Thongprayoon, Pradeep Vaitla, Iasmina M Craici, Napat Leeaphorn, Panupong Hansrivijit, Sohail Abdul Salim, Tarun Bathini, Franco H Cabeza Rivera, Wisit Cheungpasitporn

Open access · goldAbstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Post-Transplant Surveillance and Management of Chronic Active Antibody-Mediated Rejection in Renal Transplant Patients in Europe.Transplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Charat ThongprayoonDivision of Nephrology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Pradeep VaitlaDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Iasmina M CraiciDivision of Nephrology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Napat LeeaphornRenal Transplant Program, University of Missouri-Kansas City School of Medicine/Saint Luke's Health System, Kansas City, MO 64111, USA.
Panupong HansrivijitDepartment of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA 17105, USA.
Sohail Abdul SalimDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Tarun BathiniDepartment of Internal Medicine, University of Arizona, Tucson, AZ 85724, USA.
Franco H Cabeza RiveraDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
Wisit CheungpasitpornDivision of Nephrology, Department of Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.
University of Mississippi Medical Center · USMayo Clinic in Arizona · USSaint Luke's Health System · USUniversity of Arizona · USUPMC Central Pa · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patient monitoring after kidney transplantation (KT) for early detection of allograft rejection remains key in preventing allograft loss. Serum creatinine has poor predictive value to detect ongoing active rejection as its increase is not sensitive, nor specific for acute renal allograft rejection. Diagnosis of acute rejection requires allograft biopsy and histological assessment, which can be logistically challenging in some cases and carries inherent risk for complications related to procedure. Donor-derived cell-free DNA (dd-cfDNA), DNA of donor origin in the blood of KT recipient arising from cells undergoing injury and death, has been examined as a potential surrogate marker for allograft rejection. A rise in dd-cfDNA levels precedes changes in serum creatinine allows early detections and use as a screening tool for allograft rejection. In addition, when used in conjunction with donor-specific antibodies (DSA), it increases the pre-biopsy probability of antibody-mediated rejection (ABMR) aiding the decision-making process. Advancements in noninvasive biomarker assays such as dd-cfDNA may offer the opportunity to improve and expand the spectrum of available diagnostic tools to monitor and detect risk for rejection and positively impact outcomes for KT recipients. In this this article, we discussed the evolution of dd-cfDNA assays and recent evidence of assessment of allograft rejection and injury status of KT by the use of dd-cfDNA.

Indexed as

biomarkerscfDNAddcfDNAdonor derived cell free DNAdonor-derived cell-free DNAkidneykidney transplantationnephrologyrenal transplantationtransplantation

Identifiers

PMID32423115
PMCPMC7290747
OpenAlexW3025446704

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.